Match tier
Listed
Presence
Current · Arkansas
Last published
2026
Sources
OpenAlex · ORCID
Refreshed
2026-10-05
K
Kanishka Manna
Postdoctoral Associate
Also affiliated: University of California, Los Angeles (2022); University of Arkansas Medical Center (2026); UCLA Jonsson Comprehensive Cancer Center (2022)
2 h-index
7 pubs
23 cited
Research Areas
Biomedical Subjects
Links
Biography and Research Information
OverviewAI-generated summary
Kanishka Manna's research focuses on the application of proteogenomics to understand cancer biology, particularly in the context of treatment resistance. Manna has co-authored publications investigating multi-omics data integration for triple-negative breast cancer and exploring proteogenomic analysis to identify acquired resistance-specific alterations in melanoma patient-derived xenografts (PDXs) treated with MAPKi therapy. Their work also includes the development of protocols for proteogenomics reference databases. Manna has collaborated extensively with researchers at the University of Arkansas for Medical Sciences, including Michael Scott Robeson, Charity L. Washam, Duah Alkam, and Samuel G. Mackintosh, with whom they have co-authored multiple publications. Manna's scholarship metrics include an h-index of 2 across 6 publications with 21 citations.
Metrics
- h-index: 2
- Publications: 7
- Citations: 23
Positions
-
Postdoctoral Associate 2025–presentThe University of Arizona College of Medicine Translational Neuroscience ORCID
-
Postdoctoral Associate publications 2021–2026University of Arkansas for Medical Sciences ORCID
-
Postdoctoral Scholar 2024–2025University of Nevada, Reno Research & Innovation ORCID
-
Research Assistant 2020–2023University of Arkansas for Medical Sciences Biochemistry and Molecular Biology ORCID
Selected Publications
-
Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy (2023)
-
Proteogenomics Reference Database Protocol v1 (2022)
-
Proteogenomics Reference Database Protocol v1 (2022)
-
Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model (2022)
-
Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy (2022)
-
Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer (2021)
Collaboration Network
Top Collaborators
Stephanie D. Byrum
University of Arkansas for Medical Sciences
6 shared publications
In database
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
Showing 5 of 6 shared publications
Charity L. Washam
University of Arkansas for Medical Sciences
5 shared publications
In database
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Duah Alkam
University of Arkansas for Medical Sciences
5 shared publications
In database
- Multi-omics data integration reveals correlated regulatory features of triple negative breast cancer
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Michael S. Robeson
University of Arkansas for Medical Sciences
5 shared publications
In database
- Short-Term Metformin Treatment Enriches Bacteroides dorei in an Obese Liver Steatosis Zucker Rat Model
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Prashanthi Dharanipragada
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Nathan L. Avaritt
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Samuel G. Mackintosh
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Zhentao Yang
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Shirley H. Lomeli
University of California, Los Angeles (US)
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Gatien Moriceau
4 shared publications
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Alan J. Tackett
University of Arkansas for Medical Sciences
4 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Tung-Chin Chiang
University of Arkansas for Medical Sciences
3 shared publications
In database
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Roger S. Lo
University of California, Los Angeles (US)
3 shared publications
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Ricky D. Edmondson
University of Arkansas for Medical Sciences
2 shared publications
In database
- Proteogenomics analysis to identify acquired resistance-specific alterations in melanoma PDXs on MAPKi therapy
- Proteogenomics Analysis to Identify Acquired Resistance-Specific Alterations in Melanoma PDXs on MAPKi Therapy
Yan Wang
University of Arkansas at Little Rock (US)
2 shared publications
- Proteogenomics Reference Database Protocol v1
- Proteogenomics Reference Database Protocol v1
Similar Researchers
Based on overlapping research topics
Charles Matthew Quick
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Disease Models, Animal
Benjamin J. Swanson
University of Arkansas at Fayetteville
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Disease Models, Animal
Meagan B. Myers
National Center for Toxicological Research
Cancer-related molecular mechanisms research
Genomics and Phylogenetic Studies
Disease Models, Animal
Alex L. McDonald
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Models, Animal
Medical Research
Ying-Zhi Xu
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Models, Animal
Drug Transport and Resistance Mechanisms
César Sánchez
University of Arkansas for Medical Sciences
Cancer-related molecular mechanisms research
Disease Models, Animal
Drug Transport and Resistance Mechanisms